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Introduction
Rheumatoid arthritis (RA) is an immune-mediated chronic inflammatory joint disease caused by a combination of genetic and environmental factors. The overall heritability of RA is estimated to be around 50% and the major histocompatibility complex (MHC) region is the single most important genetic risk locus. 1 In schizophrenia, there is also accumulating evidence for a role of immune signaling. 2 For example, an increased peripheral concentration of IL-1 receptor antagonist (IL-1Ra) has been reported in patients with schizophrenia 3 and knockout mice lacking IL-1Ra develop spontaneous joint inflammation. 4 Recent genome-wide association studies (GWAS) of schizophrenia have also found strong associations with markers spanning the MHC region, 5 indicating a possible role for adaptive immunity also in schizophrenia.
Numerous epidemiological studies have described an inverse association between RA and schizophrenia. [6] [7] [8] [9] The association remains poorly understood but has been suggested to be due to a shared immune-related aetiology, 10 possibly attributed to genetic factors. 7, 8 The majority of these studies have assessed the risk of RA in patients with schizophrenia.
Since the typical age of onset is higher in RA than in schizophrenia, such assessments may be biased by under-reporting or under-diagnosis of RA in patients with severe mental disorders. 7 An alternative approach that would largely circumvent such differential misclassification bias, and also reveal potential common genetic determinants, would be to assess the risk of RA in first-degree relatives of probands with schizophrenia, and vice versa. Furthermore, "RA" is a criteria-based diagnosis that contains aetiologically distinct subtypes, e.g., as defined by the presence of serological markers. Recent studies of RA also suggest that seronegative and seropositive RA, the latter defined by presence of rheumatoid factor (RF) and/or anti-citrullinated peptide/protein antibodies (ACPA), have different aetiologies and genetic architectures.
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The MHC is most strongly associated with ACPA-positive RA. [12] [13] [14] Most, but not all, ACPA-positive patients are also RF-positive, and it is estimated that 50-80% of all individuals with RA have RF, ACPA, or both. 15 Hence, a comprehensive assessment of the association between RA and schizophrenia needs to take RA subtype into account.
So far, attempts to study familial associations between RA and schizophrenia have not provided conclusive results, mainly because of small samples yielding limited statistical precision. Of the four existing studies -none of which were primarily designed to assess a familial association between schizophrenia and RA -one study, based on interviews with mothers of psychotic patients (n=101), found that RA was significantly less common in the mothers, but no association with RA in the patients' first-degree relatives overall was observed. 16 In a second, larger study based on national registries, parents of schizophrenia patients had a higher than expected prevalence of RA, 17 although this association did not reach statistical significance. In a third study, based on 515 RA patients and 769 controls, 23 subjects had a family-history of schizophrenia, and the observed relative risk of approximately 2 did not reach significance. 18 However, in the same study, patients with RA characterized by the presence of ACPA were at increased risk of having a first-degree relative with schizophrenia whereas no such association was seen in ACPA-negative RA. The fourth and most recent study explored the risk of autoimmune diseases, including RA, in individuals with a family history of schizophrenia spectrum disorder using Danish nationwide registers. 9 294 out of 9 697 individuals with a register-based diagnosis of RA had a parent or sibling with a diagnosis of schizophrenia but the risk was not different from that of the general population.
In this study, we aimed to assess the relative risk of RA in patients with schizophrenia and in their first-degree relatives (children, siblings, and parents), using a sufficiently large study population and -to the extent possible -assess these risks in relation to seropositive and seronegative RA (as defined by the 10th revision of the International Classification of Diseases (ICD-10)). 19 Also in contrast to previous studies, we assessed the risk of schizophrenia in first-degree relatives of RA probands. To gauge effects primarily related to diagnostic intensity, we also assessed risks of RA in patients with schizoaffective and bipolar disorder (BD). We furthermore investigated the risks of noninflammatory musculoskeletal diseases (osteoarthritis [OA] ) and inflammatory non-RA diseases (ankylosing spondylitis [AS]) in patients with these three major psychotic disorders and in their first-degree relatives.
Methods

Data sources used
All residents in Sweden receive a 10-digit personal identification number, which is consistent throughout all national registries, and hence make register linkage possible. 
Source population
The study population was defined as every individual identified in the Swedish population register born in Sweden between January 1932 and December 1989.
Immigrants were included if less than 18 years old when registered in Sweden or if they immigrated as an adult before January 1958. The study was approved by the Ethics committee at Karolinska Institutet, Stockholm, Sweden.
Identification of schizophrenia and other psychiatric diagnoses
The inpatient component of the NPR contains all public psychiatric inpatient admissions on at least one visit in the NPR listing this diagnosis, while a previously validated algorithm, based on two or more separate registrations in the NPR, was used to identify BD subjects. 23 The diagnostic structure was non-hierarchical, meaning that a subject could have more than one diagnosis. All diagnostic codes were retrieved from the NPR and the ICD codes used are listed in eTable 1.
Identification of RA and other musculoskeletal diagnoses
Subjects with RA were identified based on at least one visit in the NPR listing a RA diagnosis from 1997 and through 2009. Start of follow-up was in 1997 when ICD-10 was introduced in Sweden (previous ICD classifications do not separate seropositive and seronegative RA). To assess effects related to the RA diagnosis per se rather than effects related to musculoskeletal symptoms or access to (rheumatology) care, we also identified all subjects with at least one visit in the NPR listing a diagnosis of OA or AS (eTable 1).
Study design
We performed cohort analyses using prospectively recorded register-data. In the intraindividual analyses, we assessed the association between schizophrenia (exposure) and risk of RA (outcome). In the familial analyses, we assessed the association between having a first-degree relative with schizophrenia (exposure) and risk of RA overall and by subtype (outcome). We also performed analyses of the risk of schizophrenia in firstdegree relatives of patients with RA overall and by subtype. For comparison reasons, the same analyses were also run for schizoaffective disorder and BD (instead of schizophrenia), and for AS and OA (instead of RA).
Statistical analyses
We first analyzed intra-individual risks of developing RA overall and by subtype, AS, and OA following a diagnosis of schizophrenia, schizoaffective disorder, or BD, respectively. We used Cox regression models with attained age as time-scale and all analyses were adjusted for sex. All subjects in the study population were followed from birth (or January 1st 1997 if born before this date). Exposure was treated as a timevarying covariate, such that a person was considered as unexposed before the date of the first psychiatric diagnosis, and as exposed thereafter. Follow-up ended with first diagnosis of the rheumatological outcome under study, death, emigration, or on December 31st 2009. Regarding risk of RA overall, we also performed additional analyses using the full study period (start of follow-up in 1973). In a sensitivity analysis of RA by subtype, we excluded patients with an RA overall diagnosis before start of follow-up in 1997.
We then assessed the risk of RA (overall and by subtype), AS, and OA in first-degree relatives of patients with the psychotic disorder under study compared to that of firstdegree relatives of non-patients. Conversely, we also assessed the risk of the psychotic disorder under study in first-degree relatives of patients with these rheumatological disorders. To verify that the study design was able to identify the anticipated diseasespecific familial associations, we performed additional analyses to assess risk of the disorder under study in first-degree relatives of individuals with this disorder. We used Cox regression with robust sandwich confidence intervals (attained age as time-scale).
Exposure was time-varying, here meaning that first-degree relatives were considered unexposed up until the date of first occurrence of the proband's first diagnosis, and as exposed thereafter. Follow-up began at birth (or January 1st 1997) and ended with first occurrence of the outcome diagnoses, end-of-follow-up (December 31st 2009), death, or emigration. All analyses were adjusted for sex.
Results
We 
Verification of the familial study design; disease-specific familial associations
Disease-specific familial risks were similar to what has been shown in previous studies. 1A and 1B) . We also performed the same analyses only counting exposure from 1st January 1997 and onwards, i.e., probands diagnoses before this date were not taken into account regarding exposure of the first-degree relatives, with similar results (data not shown). 
Risk of schizophrenia in first-degree relatives of individuals with RA by subtype
Discussion
In line with previous reports, we found a significantly decreased risk for RA in subjects with a history of schizophrenia. The risks for OA, a non-inflammatory joint disorder, and for AS, a non-RA inflammatory disorder, were however similarly decreased, suggesting that a substantial part of the observed inverse association between RA and schizophrenia may be due to other factors than disease-specific biology. This finding is consistent with the results from a prior study reporting a comparable incidence of degenerative musculoskeletal disorders and RA in schizophrenia patients. 7 Further, we found no associations between BD and RA despite a previous study's report of a shared polygenic component of schizophrenia and BD of 68%. 25 In light of the more severe loss of function in schizophrenia and schizoaffective disorder patients in comparison to BD patients, 26 this is compatible with differential misclassification bias in the observed inverse association between schizophrenia and RA. Interestingly, patients with schizophrenia or related psychosis, have been reported to be at increased risk of other autoimmune diseases. 9 Hence, if under-reporting or under-diagnosis of RA explains most of the inverse association, such differential misclassification bias is most certainly sensitive to both type and severity of symptoms. Of clinical importance, these data however emphasize the need of assessing and being aware of non-psychiatric symptoms in schizophrenia patients.
In the analyses of first-degree relatives of schizophrenia probands, we observed no significant associations with RA overall. However, analyzing RA risk by subtype, we observed a significantly decreased risk for seronegative RA in children (HR=0.13) and siblings (HR=0.67) of schizophrenia probands. Correspondingly, the lowest point estimate for schizophrenia was observed in relatives of seronegative RA patients (HR=0.54), and the lowest point estimate among schizophrenia patients was also observed for seronegative RA (HR=0.49). This was unexpected, as the strongest link with MHC has been found for seropositive RA. On the other hand, since seronegative RA is considerably less common than seropositive RA, and may in itself be a heterogeneous entity, less is known about the aetiology and link to MHC in this RA subset. In BD we observed no significantly decreased risk for RA overall, or per subgroup. Molecular genetics studies also suggest a greater MHC involvement in schizophrenia compared with BD. 27 The strongest single nucleotide polymorphism (SNP) association with schizophrenia is also located in the extended MHC, 5 but the complexity of the region, including strong linkage disequilibrium (LD) and a high gene density, has complicated efforts to identify causal variations. The classical MHC I haplotype HLA-B*08 has been associated with a decreased risk of schizophrenia. [27] [28] [29] This motif is reported to predispose for RA, 30 although hitherto only shown in ACPA-positive RA patients. Both MHC class II and I are also involved in synaptic plasticity, 31.32 and a direct role for these molecules in the pathophysiology of schizophrenia is therefore possible. Importantly, the schizophrenia locus is located in a region with high LD and extends over several Mb. The strengths of our data include the national coverage and the fact that this is the largest study of intra-individual and inter-familial associations between schizophrenia and RA.
The size of our study population in combination with the number of events during followup and the duration of follow-up provided sufficient power to detect even moderate differences in risks overall and stratified RA subtype. The use of outpatient data, in combination with the hospital discharge register, also diminished the risk of bias related to hospitalization rather than the studied disease per se.
A limitation of this study is the use of diagnostic information that depends on data provided from national registries. Nevertheless, Swedish register discharge diagnoses of schizophrenia have shown a high concordance with diagnoses based on semi-structured interviews. 33 Similarly, register-based RA diagnoses have a high diagnostic accuracy and correspond to a typical RA prevalence. 34 Another drawback of the population-based approach is the limited data regarding potential confounders. For example, smoking is more common in schizophrenia patients than in their first-degree relatives, 35 and the risk of developing ACPA-positive RA is associated with a gene-environment interaction between smoking and the HLA-DRB1 SE alleles. 36 Hence, it is possible that the estimated relative risk for seropositive RA in schizophrenia patients (but perhaps not in their firstdegree relatives) was inflated by uncontrolled confounding from smoking. Of note, we also observed a significantly increased risk of seropositive RA in schizophrenia siblings.
However, confounding by smoking could hardly explain the decreased risks for seronegative RA in schizophrenia patients and their first-degree relatives. Less is known about other environmental triggers for RA, and few other robust gene-environment interactions have been reported. 1, 15 Since the heritability of RA is estimated to be around 50%, leaving the remaining part to environment and interactions, further uncontrolled confounding cannot be excluded. Finally, stratification by ACPA serostatus, in combination with RF status (i.e., ICD-10), would have further improved the specificity of the heterogeneous RA phenotype.
In conclusion, our analyses suggest that under-reporting, or under-diagnosis, is an important factor for the inverse intra-individual association of schizophrenia and RA.
However, an unexpected inverse association between seronegative RA and schizophrenia due to genetic causation cannot be ruled out. Taken together, further molecular genetic studies of the association between RA and schizophrenia should include stratification by 
